Login to Your Account

Amgen to Pay $150M in Fines, Forfeiture; More to Come

By Mari Serebrov
Washington Editor

Wednesday, December 19, 2012
Amgen Inc. began to close the book Tuesday on several federal investigations and whistleblower suits involving its marketing practices when it pleaded guilty in federal district court to a misdemeanor charge of off-label marketing of Aranesp, which posted global sales of $2.3 billion in 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription